How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.

The article discusses a study which assessed the proportion of chronic myeloid leukemia patients treated front line with imatinib outside clinical trials who could achieve a durable molecular response (MR) and maintain after treatment discontinuation. Topics covered include the reason for therapy restart, characteristics of patients who discontinued imatinib, and comparison of dasatinib and nilotinib with imatinib.